Report on recent diagnosis and treatment of acute myeloid leukemia in the 54th ASH annul meeting
10.3760/cma.j.issn.1009-9921.2013.01.002
- VernacularTitle:急性髓系白血病诊断与治疗最新进展:第54届美国血液学会年会深入报道
- Author:
Lin QIU
;
Jun MA
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Next-generation sequencing;
Minimal residual disease;
Target therapy;
Molecular marker;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2013;22(1):4-7
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is the most commom hematologic malignancy in adults.There are so many highlights in the 54th ASH annual meeting in the field of mechanism,diagnosis and treatment of AML.Especially many studies have identified genes close related to AML development,clones related to relapse and molecular marker for prognosis using next-generation sequencing (NGS).Minimal residual disease (MRD) assay has been used for evaluation of therapy efficacy and posttherapy prognostication in AML treatment.The tyrosine kinase inhibitor targeting FLT3-ITD in this meeting is the best highlight in the treatment of refractory and relapsed AML.
